Progressive forms of MS: Classification streamlined or consensus overturned?

Lancet

Volumn 355, Issue 9199, 2000, Pages 162-163

  Weinshenker, Brian G ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE CLASSIFICATION; DISEASE COURSE; HUMAN; MULTIPLE SCLEROSIS; NOTE; PRIORITY JOURNAL;

EID: 0034650738     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)00356-6     Document Type: Note

References (19)

1. McAlpine D., Compston N., Lumsden C. Multiple sclerosis. 1996;Livingstone, Edinburgh.
2. Kurtzke J., Beebe G., Nagler B.et al. Studies on the natural history of multiple sclerosis VIII. Early prognostic features of the later course of the illness. J Chronic Dis. 30:1977;819-830.
3. Weinshenker B.G., Rice G.P.A., Noseworthy J.H., Carriere W., Baskerville J., Ebers G.C. The natural history of multiple sclerosis: a geographically based study. Brain. 114:1991;1045-1056.
4. Runmarker B., Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with 25 years of follow up. Brain. 116:1993;117-134.
5. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Neurology. 43:1993;655-661.
6. Lublin, F.D., Reingold, S.C, (USA) NMSS. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996; 46: 907-11.
7. Thompson A., Polman C., Miller D.et al. Primary progressive multiple sclerosis. Brain. 120:1997;1085-1096.
8. Olerup O., Hillert J., Fredrikson S.et al. Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities. Proc Natl Acad Sci USA. 86:1989;7113-7117.
9. Weinshenker B., Santrach P., Bissonett A.et al. Major histocompatibility complex class II alleles and the course and outcome of multiple sclerosis: a population-based study. Neurology. 51:1998;742-747.
10. Thompson A., Montalban X., Barkhof F.et al. New diagnostic criteria for primary progressive multiple sclerosis. Ann Neurol. 46:1999;471.
11. Kremenchutzky M., Cottrell D., Rice G.et al. The natural history of multiple sclerosis: a geographically based study 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain. 122:1999;1941-1949.
12. Andersson P.B., Waubant E., Gee L., Goodkin D.E. Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disability. Arch Neurol. 56:1999;1138-1142.
13. Trapp B., Peterson J., Ransohoff R., Rudick R., Mork S., Bo L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338:1998;278-285.
14. Matthews P.M., De Stefano N., Narayanan S.et al. Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis. Semin Neurol. 18:1998;327-336.
15. Kappos, L., and the European Study Group on Interferon beta-1b in secondary-progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-97.
16. Lucchinetti C.F., Brück W., Rodriguez M., Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol. 6:1996;259-274.
17. Lucchinetti C.F., Brück W., Parisi J., Scheithauer B., Rodriguez M. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions: a study of 113 cases. Brain. 122:1999;2279-2295.
18. Lucchinetti C.F., Brueck W., Rodriguez M., Lassmann H. Multiple sclerosis: lessons from neuropathology. Semin Neurol. 18:1998;337-349.
19. Weinshenker B., O'Brien P., Petterson T.et al. A randomized trial of plasma exchange in acute CNS inflammatory demyelinating disease. Ann Neurol. 16:1999;878-889.